ArticleMolecular medicine reports2026
MALT1 inhibition by MI‑2 suppresses epithelial‑to‑mesenchymal transition and fibrosis by inactivating the NF‑κB pathway in high glucose‑treated HK‑2 cells.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosa‑associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a scaffold protein and protease that is associated with multiple biological processes, such as immune signaling transduction, inflammation and glucose variation. However, its implication in diabetic nephropathy (DN) is unclear. The present study aimed to investigate the dysregulation of MALT1 and the effect of its inhibition by MI‑2 in high glucose‑treated renal tubular epithelial cells. HK‑2 cells were treated with 15 mM D‑glucose [low‑concentration glucose (LG) group] and 30 mM D‑glucose [high‑concentration glucose (HG)]. The negative control (NC) group consisted of cells cultured only with the standard medium. Subsequently, HK‑2 cells under the HG condition were treated with 0, 1, 2 and 4 µM MI‑2, an inhibitor of MALT1. Cell migration rate, invasive cell count, and the expression levels of vimentin, α‑smooth muscle actin (α‑SMA), fibronectin (FN) and collagen I were increased, whereas E‑cadherin expression was decreased in the HG group compared with that in the NC group (all P<0.01), implying enhanced epithelial‑to‑mesenchymal transition (EMT) and fibrosis in the HG group. Furthermore, MALT1 was upregulated in the HG group compared with that in the NC group (P<0.01). Following MI‑2 treatment in cells under the HG condition, the inhibitory effects of MI‑2 on EMT, fibrosis and the NF‑κB pathway were dose‑dependent. Cell migration rate, invasive cell count and vimentin expression were reduced, whereas E‑cadherin expression was elevated; furthermore, the expression levels of α‑SMA, FN and collagen I were downregulated in the high concentration MI‑2 (HC‑MI‑2) group compared with those in the HG group (all P<0.01). In addition, the NF‑κB pathway was inactivated, as reflected by increased inhibitor of κB α expression and decreased phosphorylated-p65 expression in the HC‑MI‑2 group compared with in the HG group (both P<0.001). In conclusion, MALT1 inhibition by MI‑2 suppresses EMT and fibrosis by inactivating the NF‑κB pathway in HG‑treated HK‑2 cells, indicating its potency as a target for DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.